In addition, IL-33 treatment is indicated to upregulate PD-1 expression in a fraction of tumor ILC2s; thus, a combination treatment of recombinant IL-33 and anti-PD-1 may maximally activate and enrich ILC2s in PC and enhance tumor control. This evidence concerns the gene IL33 and neoplasm.